Price
Target price
€0.89
€0.89
2.190%
0.019
2.190%
-
24.04.24 / Stuttgart Stock Exchange
WKN: A3DWPN / Name: Acelrx Pharmaceuticals / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Acelrx Pharmaceuticals Inc. Stock
Acelrx Pharmaceuticals Inc. gained 2.190% today.
Our community identified positive and negative aspects for Acelrx Pharmaceuticals Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Acelrx Pharmaceuticals Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Acelrx Pharmaceuticals Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acelrx Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acelrx Pharmaceuticals Inc. | 2.190% | -7.356% | -14.469% | 45.805% | 22.740% | -95.607% | -98.629% |
| Ardelyx Inc. | -2.530% | -2.116% | -15.296% | 40.514% | 4.048% | -12.204% | - |
| Salarius Pharmaceuticals Inc. | -3.170% | 2.315% | -15.000% | -67.971% | -20.360% | -98.187% | -99.994% |
| Brainstorm Cell | 1.170% | -1.874% | -1.485% | -81.975% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-27
When assessing the financial health of AcelRx Pharmaceuticals, a key player in the biotechnology and medical research industry, an initial review of their financials suggests a company facing significant challenges. With a market capitalization of just over $10.7 million, it's evident that AcelRx Pharmaceuticals is a relatively small player in the sector, likely reflective of its niche focus or the early stage of its business life cycle.
Looking at the figures more closely, several elements stand out that merit a mixed evaluation, taking into account both the positive aspects and the reasons for concern.
Positive Aspects of AcelRx Pharmaceuticals Financials:
